Results 81 to 90 of about 20,104,039 (259)
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
Swiss Medical Weekly, 2012 Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of
Darius Moradpour +2 more
doaj +1 more source
Hepatitis C virus evasion mechanisms from neutralizing antibodies [PDF]
, 2011 Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. The majority of infected individuals develop chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma.
Angus, Allan G.N. +5 more
core +1 more source
New treatments for chronic hepatitis C
The Korean Journal of Hepatology, 2010 Treatments for chronic hepatitis C has evolved significantly in the past 15 years. The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks in patients infected with HCV genotype 1 or 2/3, respectively. The treatment duration can be individualized based on the baseline viral load and the speed of the virologic ...
Jang, Jae Young, Chung, Raymond
openaire +4 more sources
Arthritis Care &Research, Accepted Article.Objective Routine liver enzyme monitoring is advocated while on allopurinol but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzymes in gout patients commenced on allopurinol. Methods 150 patients with gout and normal baseline serum aminotransferases initiated on allopurinol were followed ...
May Shuen Tang +4 more
wiley +1 more source
Hepatite crónica: o espectro etiológico. Implicações para o tratamento.
Acta Médica Portuguesa, 1993 The prevalence of chronic hepatitis and its different aetiologies was studied in all patients above 10 years of age seen in the specialised outpatient clinic of our hospital over a 3 year period.
J Velosa +4 more
doaj +1 more source
Advanced Healthcare Materials, EarlyView.FeS‐VA@lanifibranor (FVL), an activated hepatic stellate cell (aHSC)‐targeted nanoplatform comprising vitamin A‐functionalized two‐dimensional iron sulfide nanosheets and lanifibranor, is engineered for precision therapy of liver fibrosis. FVL suppresses the TGF‐β signaling pathway by inhibiting SMAD2/3 phosphorylation and induces ferroptosis in aHSCs,
Yinuo Yang +11 more
wiley +1 more source
Journal of Global Antimicrobial ResistanceOBJECTIVE: This study aims to investigate the Hepatitis C Virus (HCV) genotypes, changes in genotype distribution, and the effects of migration among chronic hepatitis C patients who presented at a university hospital in Diyarbakır over a decade ...
Esra Yenihal +3 more
doaj +1 more source
Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil
Brazilian Journal of Infectious Diseases, 2018 Background and aims: Hepatitis E virus infection in patients with underlying chronic liver disease is associated with liver decompensation and increased lethality.
Guilherme Bricks +9 more
doaj +1 more source
Jurnal Penyakit Dalam Indonesia, 2020 Hepatitis C infection is often found in asymptomatic patients accidentaly during general check up, where there is increment levels of transaminases. Symptoms of hepatitis C infection include weakness, sleep disorders, nausea and so on.
Jefri Pratama Susanto +2 more
doaj +1 more source
Modulation of miR‐23b Wnt/β‐catenin Axis Strengthens Endothelial Barrier Properties
Advanced Science, EarlyView.Early blood‐brain barrier (BBB) disruption contributes to stroke and CNS disease pathology. miR‐23b was identified as a regulator of BBB integrity in brain endothelial cells. Inhibition of miR‐23b enhanced barrier‐associated properties, promoted repair‐related signaling, and reduced BBB leakage in experimental stroke models, supporting further ...
Victor Anthony Martinez +16 more
wiley +1 more source